Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05208047 · ClinicalTrials.gov registry record · Phase 3
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
A Phase 3 study of Metastatic Cancer and Advanced Gastrointestinal Stromal Tumors, sponsored by Cogent Biosciences.
- Active
- Registry status
- Phase 3
- Development phase
- 442
- Enrollment target
- 20
- Study locations
NCT05208047 is a Phase 3 study of Metastatic Cancer and Advanced Gastrointestinal Stromal Tumors that is active but no longer recruiting, run by Cogent Biosciences. The registered enrollment target is 442 participants, roughly in line with the 440-participant average among 109 other Metastatic Cancer trials with a reported enrollment target. The trial reports 20 study locations across 13 states.
The verdict
NCT05208047, a Phase 3 study of Metastatic Cancer and Advanced Gastrointestinal Stromal Tumors, is active but no longer recruiting, sponsored by Cogent Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 442 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 442 patients. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to be used in subsequent parts in approximately 20 patients who have received at least one prior line of therapy for GIST and 2) evaluating the potential for drug-drug interactions between CGT9486 and sunitinib in approximately 18 patients who have received at least two prior tyrosine kinase inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388 patients who are intolerant to, or who failed prior treatment with imatinib only and will compare the efficacy of CGT9486 plus sunitinib to sunitinib alone with patients being randomized in a 1:1 manner. Additionally, a drug-drug interactions substudy will investigate the potential for CGT9486 to be a CYP3A4 inducer in approximately 16 patients who have received at least one prior line of therapy for GIST.
Conditions Studied
Interventions
- DRUG Midazolam
- DRUG Sunitinib
- DRUG CGT9486 plus sunitinib
- DRUG CGT9486
Study Locations (20)
California
- City of Hope - Duarte
- University of California, Los Angeles (UCLA) - Los Angeles
- University of California, San Diego (UCSD) - San Diego
- University of California, San Francisco - San Francisco
Florida
- Mayo Clinic Jacksonville - Jacksonville
- University of Miami - Sylvester Comprehensive Cancer Center - Miami
- Orlando Health Cancer Institute - Orlando
- Moffitt Cancer Center - Tampa
Arizona
- Mayo Clinic - Scottsdale
- University of Arizona- Cancer Center - Tucson
Colorado
- University of Colorado Denver - Denver
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Illinois
- Northwestern University - Chicago
Iowa
- University of Iowa Hospital and Clinics - Iowa City
Kansas
- University of Kansas Cancer Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 442 participants |
| Start Date | 2022-04-14 |
| Est. Completion | 2026-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05208047
The ClinicalTrials.gov registry entry for NCT05208047 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 442 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 440-participant average among 109 other Metastatic Cancer trials with a reported enrollment target. The listed sponsor is Cogent Biosciences, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 4 interventions - of which Midazolam is the first listed.
NCT05208047 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT05208047 about?
NCT05208047 is a clinical study titled "(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors". This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 442 patients. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to be used in subsequent p...
What is the current status of trial NCT05208047?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 442 participants. The study started on 2022-04-14. Estimated completion is 2026-09.
What conditions does trial NCT05208047 study?
This clinical trial studies the following conditions: Metastatic Cancer, Advanced Gastrointestinal Stromal Tumors.
What interventions are being tested in trial NCT05208047?
The interventions under investigation include: Midazolam (DRUG), Sunitinib (DRUG), CGT9486 plus sunitinib (DRUG), CGT9486 (DRUG).
Who is sponsoring clinical trial NCT05208047?
This trial is sponsored by Cogent Biosciences, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05208047 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
RECRUITING · Phase 3
-
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
COMPLETED · Phase 3
-
Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
COMPLETED · Phase 3
-
Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases
COMPLETED · Phase 3
-
Talc in Treating Patients With Malignant Pleural Effusion
COMPLETED · Phase 3
-
Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.